Cyril Kanto, M.D.

Cyril Kanto, M.D., is an oncologist and the CEO of Ichnos Glenmark Innovation, specializing in biologics and multispecific antibody platforms. He discusses the breakthrough potential of multispecific antibodies and the strategic $700 million deal with AbbVie. Cyril shares insights on navigating the challenging biotech landscape, the role of collaboration in innovation, and the shift from animal models to advanced in silico modeling. He also explores the impact of China's biotech sector and emphasizes IGI's focus on emerging markets, driving forward patient-centered therapies.